TABLE 1.

FDA‐ Approved Nano medicines delivering for AD.

Carrier	Drug	Carrier material	Reference
Polymeric nanoparticles	Donepezil	Chitosan, PLGA (polysorbate 80‐coated), PLGA‐b‐PEG	Bhavna et al., 2014 & Baysal I et al., 2017 [192, 193]
	Galantamine	Chitosan, PLGA	Fornaguera C et al., 2015 [194]
	Rivastigmine HCl	Chitosan	Fazil M et al., 2012 [195]
	Rivastigmine Tartrate	PLGA, chitosan, PBCA	Joshi SA et al., 2010 & Khemariya RP et al., 2016 [196, 197]
Solid lipid nanoparticles	Galantamine	Glycerylbehnate (Compritol)	Misra S et al., 2016 [198]
	Lipoyl–Memantine	Stearic acid	Laserra S et al., 2015 [199]
	Rivastigmine HCl	Compritol 888 ATO	Shah B et al., 2015 [200]
Liposomes	Rivastigmine HC	Phosphatidylcholine; Dihexadecyl phosphate; cholesterol; glycerol	Ismail MF et al., 2013 [201]
	Donepezil	Carboxymethyl cellulose, 1,2‐distearyl‐sn‐glycero‐3‐phosphocholine, cholesterol, PEG	Al Asmari AK et al., 2016 [202]
CPP‐modified liposomes	Rivastigmine HCl	EPC, cholesterol, DSPE‐PEG‐CPP	Yang ZZ et al., 2013 [203]
Flexible liposomes	Galantamine	Soya phosphatidylcholine, cholesterol, and propylene glycol as edge activator	Li W et al., 2012 [204]

Abbreviations: CPP, Cell‐Penetrating Peptide; DSPE, 1,2‐Distearoyl‐sn‐Glycero‐3‐Phosphoethanolamine, EPC, Egg Phosphatidylcholine; PEG, Polyethylene Plycol, PBCA, Oolybutyl Cyano Acrylate; PLGA, poly Lactide‐co‐Glycolic Acid.